Rare genetic-disease focused firm BioMarin Pharmaceutical has added a four-storied laboratory to its Cork, Ireland facility.

The Cydem VT system combines multiple trusted Beckman Coulter Life Sciences technologies into one advanced platform that empowers lab managers with a far more effective, higher-throughput method for ...

Cell line development involves the screening of thousands of clones in an effort to find the few optimal clones that are stable, grow as expected, and produce high yields of the bioproduct. The time ...

Announced in 2021, the facility, named Modulus, is expected to be fully operational by 2026 and will create about 200 jobs locally. Modulus is Sanofi’s first "EVolutive vaccine facility (EVF)" outside ...

Articles In Color Color reprints are printed on 70# enamel paper and can be reproduced in color or in black and white. Color articles reprinted in black and white will be charged black and white ...

This website (the “Site”) is operated by Informa Connect, a trading division of the Informa Group. The parent company of the Informa Group is Informa PLC. Informa Connect (“Informa Connect”, “we” or ...

The Cydem VT system combines multiple trusted Beckman Coulter Life Sciences technologies into one advanced platform that empowers lab managers with a far more effective, higher-throughput method for ...

The firm has received a $50 million investment from Texas-based financial aid company Vitrian. This investment includes an option to increase funding up to $65 million. The initial aid will support ...

Glucagon-like peptide-1 (GLP-1) drugs for diabetes and weight loss are emerging as the latest blockbuster pharmaceuticals. Like messenger RNA (mRNA) gaining recognition during the pandemic, the ...

The contract development and manufacturing organization (CDMO) is adding drug delivery technology to its headquarters, while it has broken ground at its 545,000 square-foot Rockford, Illinois site.

Multichain protein biotherapeutics such as bispecific molecules have been developed to treat cancer, neurological and ophthalmic disorders, and autoimmune and inflammatory diseases. Early successes ...